Recordati details March buy-back trades and stock option-related treasury share sales

Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has issued an update.

Recordati has disclosed a series of March 2026 transactions involving its own shares, tied both to employee stock option plans and to a previously announced share buy-back programme. The company sold treasury shares directly to beneficiaries exercising stock options at their pre-set exercise prices, while UBS Europe SE, acting as intermediary, repurchased Recordati shares on the Euronext Milan market on multiple trading days, signalling ongoing capital management and shareholder-remuneration activity.

The buy-back trades, executed between 2 and 20 March 2026 on the EXM segment, covered multiple tranches ranging from a few thousand to over 50,000 shares per day, at average prices broadly in the mid-40 euro range. These operations incrementally adjust Recordati’s treasury share position, supporting its stock-based incentive plans and potentially influencing share liquidity and capital structure, with implications for existing shareholders and future corporate finance flexibility.

The most recent analyst rating on (IT:REC) stock is a Buy with a EUR56.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian pharmaceutical company based in Milan and listed on the Italian stock market. The group develops and markets prescription medicines and specialty pharmaceuticals, with a focus on both primary care and specialty therapeutic areas across international markets.

Average Trading Volume: 369,065

Technical Sentiment Signal: Buy

Current Market Cap: €10.32B

Learn more about REC stock on TipRanks’ Stock Analysis page.